Document is current
Any future updates will be listed below
-
Authors
Moutinho, Daniela
Mendes, Vera M.
Caula, Alessandro
Madeira, Sara C.
Baldeiras, Inês
Guerreiro, Manuela
Cardoso, Sandra
Gobom, Johan
Zetterberg, Henrik
Santana, Isabel
De Mendonça, Alexandre
Aidos, Helena
Manadas, Bruno http://orcid.org/0000-0002-2087-4042
-
Funding
Funding for this research was provided by:
Fundação para a Ciência e a Tecnologia (PTDC/MED-NEU/27946/2017)
- License Information
-
More Information
Article History
Received: 29 December 2023
Accepted: 22 March 2024
First Online: 9 April 2024
Declarations
:
: Participants were selected from the Cognitive Complaints Cohort (CCC) and recruited at Memoclínica, a private memory clinic in Lisbon, Portugal. The CCC was established in a prospective study conducted at the Faculty of Medicine, University of Lisbon, approved by the local ethics committee, conducted according to the Declaration of Helsinki and requiring the participants’ informed consent [CitationRef removed].
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
